AddLife AB (publ) (ALIF_B) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and a warm welcome to the AddLife first quarter presentation. As usual, we will be going through the developments in the different parts of the business as well as the financials, and after that, open up for questions. After the Q and A session, we have prepared a video from one of our subsidiaries, this time around Bonsai Lab, so we do encourage you to stay on to listen to that very interesting video. So let's move on to the highlights of the quarter. So in the first quarter, we're pleased to note that this high margins continue and at the same time we are increasing the acquisition activity. The EBITDA margin remained high at 12.5%, only slightly below the very high levels of Q1 in 2025. In Labtech, which had a really strong quarter, we saw an increase of one percentage point to 13.1% margin, very, very strong. On the MedTech side, we were able to retain almost 13% EBITDA margin, even though it's slightly below the record level of 13.5 in Q1 of twenty twenty five. The underlying demand in all businesses is quite solid, and if we exclude the divested endoscopy business in The UK, we saw an organic growth on a group level at 3%. It's also worth to note that we had a fantastic finish to 2025. So the start of the quarter was somewhat more cautious, but towards the end of the quarter, the demand picked up significantly. So we had a very strong month of March. We are going to talk quite a bit about advanced products in this quarter. We are seeing a fantastic development for a broad range of advanced products, both in Lab Tech as well as in Med Tech. And we are pleased to note that since we have been able to reach and exceed our ambition level when it comes to the balance sheet, we are able to pick up the pace with acquisitions and we have done tha...